Executive Summary
Health coaches working with performance-oriented clients increasingly encounter questions about peptide science applied to endurance, strength, and recovery optimisation. This intermediate guide explores the research evidence for three performance-relevant peptide compounds — CJC-1295, Ipamorelin, and SLU-PP-332 — examining their distinct mechanisms, how they address different performance goals, and the conceptual framework for integrating this research into performance coaching conversations. Understanding the mechanistic rationale behind these compounds allows health coaches to have more evidence-informed discussions with curious high-performing clients.
Key Takeaways
- CJC-1295 (GHRH analogue) restores growth hormone-releasing hormone signalling, supporting pulsatile GH secretion for anabolic and recovery benefits.
- Ipamorelin (GHRP) selectively stimulates GH release without the cortisol/prolactin elevation of older GHRPs — making it the cleanest GH secretagogue for performance research.
- SLU-PP-332 (ERRα/ERRγ agonist) is the “exercise mimetic” — activating the same molecular pathways as endurance exercise without physical activity, with pre-clinical evidence of dramatic mitochondrial and aerobic capacity improvements.
- Stack rationale: CJC-1295/Ipamorelin address anabolic/recovery dimensions; SLU-PP-332 addresses metabolic endurance pathways — complementary, non-redundant mechanisms.
- Health coach relevance: Understanding these compounds enables evidence-based client education and referral pathways to sports medicine specialists.
Table of Contents
The Growth Hormone Axis in Performance
Growth hormone (GH) is the master anabolic and regenerative hormone, secreted in pulsatile fashion by the anterior pituitary in response to GHRH (from the hypothalamus) and ghrelin-mimicking peptides. In performance contexts, GH drives three critical processes:
- IGF-1 production — hepatic IGF-1 synthesis stimulated by GH promotes protein synthesis, satellite cell activation, and muscle hypertrophy
- Lipolysis — GH directly stimulates adipose tissue lipolysis, improving body composition and fuel availability for endurance activities
- Tissue repair — GH stimulates collagen synthesis, bone metabolism, and connective tissue integrity — all critical for sustaining high training volumes
GH secretion peaks in young adulthood and declines approximately 14% per decade from age 30, creating a progressively widening gap between training demands and hormonal support for recovery. GH secretagogue peptides address this gap by stimulating the pituitary’s endogenous GH production — a fundamentally different approach from exogenous GH administration.
CJC-1295 & Ipamorelin: The GH Stack
CJC-1295 (No-DAC)
CJC-1295 is a synthetic analogue of GHRH (Growth Hormone-Releasing Hormone), the hypothalamic peptide that drives pituitary GH secretion. The “No-DAC” (Drug Affinity Complex-free) version has a shorter half-life of approximately 30 minutes, producing a GH pulse that mimics the natural physiological pattern more closely than the DAC version (which has a ~8-day half-life and creates continuous GH elevation). For health-focused performance research, the No-DAC version is generally preferred for its preservation of natural GH pulsatility.
Ipamorelin
Ipamorelin is a selective Growth Hormone Releasing Peptide (GHRP) — the cleanest GHRP ever developed. Unlike earlier GHRPs (GHRP-2, GHRP-6) that significantly elevate cortisol, prolactin, and appetite alongside GH, Ipamorelin exclusively stimulates GH release with minimal off-target effects. Its mechanism involves ghrelin receptor (GHS-R1a) agonism in the pituitary, producing dose-dependent GH spikes without disrupting the cortisol or prolactin axes.
The CJC-1295 + Ipamorelin Synergy
The combination is mechanistically elegant: CJC-1295 restores GHRH signalling (the accelerator) while Ipamorelin independently activates ghrelin receptor-mediated GH release (a separate ignition pathway). Used together, they produce synergistic GH spikes — significantly greater than either compound alone — while the natural feedback mechanisms (somatostatin, IGF-1 feedback) remain intact, preventing supraphysiological GH accumulation. This preserved feedback regulation is what distinguishes the GH secretagogue approach from exogenous GH administration.
SLU-PP-332: The Exercise Mimetic
SLU-PP-332 represents a fundamentally different category of performance research compound. Rather than working through the endocrine system, it directly activates ERRα (Oestrogen-Related Receptor alpha) and ERRγ — transcription factors that control the expression of genes governing mitochondrial biogenesis, oxidative metabolism, and aerobic capacity. These are the same transcription factors activated by sustained endurance exercise.
Pre-Clinical Evidence
The 2023 Nature Communications study that introduced SLU-PP-332 to the broader research community showed sedentary mice treated with SLU-PP-332 for 4 weeks demonstrated:
- Significantly increased treadmill endurance capacity vs placebo controls
- Upregulation of over 700 genes associated with oxidative metabolism in skeletal muscle
- Increased mitochondrial density in Type I (slow-twitch) and Type IIa (fast-twitch oxidative) muscle fibres
- Weight loss and improved glucose metabolism, without dietary changes
The compound activates the same PGC-1α → mitochondrial biogenesis axis stimulated by Zone 2 aerobic training — the metabolic foundation underlying both aerobic performance and metabolic health. For health coaches whose clients struggle to accumulate sufficient aerobic training volume, SLU-PP-332’s exercise mimetic mechanism represents a theoretically compelling research application.
Performance Goals & Peptide Selection
| Performance Goal | Primary Compound | Mechanism |
|---|---|---|
| Muscle hypertrophy & recovery | CJC-1295 + Ipamorelin | GH → IGF-1 → protein synthesis |
| Aerobic capacity / VO2max | SLU-PP-332 | ERRα/γ → PGC-1α → mitochondrial biogenesis |
| Connective tissue resilience | CJC-1295 + Ipamorelin | GH → collagen synthesis → tendon/ligament strength |
| Body composition / fat loss | Both compounds | GH lipolysis + SLU metabolic upregulation |
| Sleep & recovery quality | Ipamorelin (pre-sleep dose) | GH surge during slow-wave sleep augmentation |
Research Protocol Frameworks
| Compound | Research Parameters | Timing | Notes |
|---|---|---|---|
| CJC-1295 (No-DAC) | 100–200mcg | Pre-sleep or pre-training | Fasted for max GH pulse |
| Ipamorelin | 200–300mcg | Co-administered with CJC-1295 | SC injection preferred |
| SLU-PP-332 | Pre-clinical data only | Daily (in rodent models) | Human research dose TBD |
Health Coach Application Framework
For health coaches, the primary value of understanding performance peptide research is the ability to provide informed, evidence-based context when clients raise these topics. Three key frameworks:
Framework 1: Mechanism-First Conversations
Rather than discussing peptides in terms of perceived outcomes, start with mechanism: “CJC-1295 restores the GHRH signal that your pituitary uses to produce growth hormone — the same signal that declines with age and limits your recovery capacity.” This framing respects the research context and helps clients understand why these compounds are studied, not just that they are.
Framework 2: Biomarker Anchoring
Help performance-oriented clients establish IGF-1 baseline levels, VO2max testing, and body composition DEXA scans before any peptide research begins. Objective data creates accountability and separates placebo effects from measurable physiological change — essential for meaningful research contribution.
Framework 3: Referral Pathway
Health coaches should maintain relationships with sports medicine physicians and endocrinologists experienced in metabolic peptide research. Identifying clients who are good candidates for supervised research requires medical evaluation that sits outside the health coaching scope of practice.
Frequently Asked Questions
SLU-PP-332 specifically targets ERRα and ERRγ transcription factors, which have broader and more direct control over oxidative metabolism gene expression than AICAR’s AMPK activation alone. GW-501516 (Cardarine) acts on PPARδ, a different pathway. SLU-PP-332’s receptor specificity and the gene expression breadth it activates in skeletal muscle distinguish it mechanistically, though human safety data remains limited.
Their mechanisms operate on entirely different axes — GH/IGF-1 endocrine axis (CJC-1295/Ipamorelin) versus nuclear receptor transcription factor activation (SLU-PP-332) — with no known pharmacokinetic interaction. The theoretical combination addresses both the anabolic/recovery dimension and the aerobic capacity/mitochondrial dimension simultaneously.
SLU-PP-332 has completed promising pre-clinical safety and efficacy studies in rodents but has not yet entered human clinical trials. Its safety profile in humans remains unknown. As an ERRα/γ agonist, theoretical concerns include effects on oestrogen-related signalling pathways and potential cardiovascular effects that require prospective human data to characterise. It should be treated as a research-stage compound with significant outstanding safety uncertainty.
GHRP-2 and GHRP-6 are earlier-generation GH secretagogues that produce significant cortisol and prolactin elevation alongside GH release — counterproductive effects in a performance context. Ipamorelin’s selectivity for the GH axis without these off-target hormonal effects makes it substantially cleaner for performance research applications where cortisol management is already a priority.
The appropriate scope for health coaches is education on mechanisms and referral to qualified medical professionals for any therapeutic application. Phrases like “research shows that CJC-1295 restores GH signalling that declines with age” are informational; advice on whether a specific client should use a compound requires medical evaluation beyond the coaching scope.
For CJC-1295/Ipamorelin: IGF-1 levels (should increase within expected physiological range), fasting GH levels, body composition via DEXA, and recovery rate metrics. For SLU-PP-332: VO2max testing, lactate threshold, mitochondrial function proxies (resting metabolic rate). Standard safety panels including glucose, HbA1c, and liver function are relevant for both.
CJC-1295 and Ipamorelin are prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). SLU-PP-332, being a newer research compound, may fall under S0 (Non-Approved Substances) on the WADA list. Athletes in sanctioned sports should assume any novel peptide compound is prohibited until confirmed otherwise through their anti-doping organisation.
DAC (Drug Affinity Complex) version extends CJC-1295’s half-life to ~8 days by covalently binding to albumin, creating sustained GHRH signalling rather than pulsatile GH peaks. No-DAC has a ~30-minute half-life, producing a more physiological pulse. For performance research, No-DAC is generally preferred because pulsatile GH release (mimicking natural physiology) is associated with superior body composition outcomes and receptor sensitivity preservation versus continuous GH elevation.
Related Articles
- CJC-1295 / Ipamorelin Stack: The Complete Bodybuilding Research Guide (2026)
- SLU-PP-332: The ERR Exercise Mimetic — 2026 Research Update
- CJC-1295 & Ipamorelin: The Complete Stack Research Guide for Athletes (2026)
Related Products
CJC-1295/Ipamorelin 10mg
Pre-combined GH secretagogue stack. No-DAC CJC-1295 + selective Ipamorelin. ≥99% purity, HPLC verified, GMP manufactured.
View GH Stack →SLU-PP-332 5mg
Research-grade ERRα/γ agonist exercise mimetic. Cutting-edge mitochondrial biogenesis research compound, third-party tested.
View SLU-PP-332 →🏋️ Total Body Transformation Plan
Our Total Body Transformation Peptide Plan integrates performance, recovery, and metabolic peptide research frameworks for health coaches and their high-performance clients.
View Transformation Plan →Scientific References
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. DOI: 10.2147/ciia.2006.1.4.307
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. DOI: 10.1016/j.sxmr.2017.02.004
- Pandya JD, Grondin Y, Rosenfeld AB, et al. Characterization and pharmacological activation of ERR to study metabolic biology. Nat Commun. 2023;14:7991. DOI: 10.1038/s41467-023-43641-8
- Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab. 1992;74(6):1378-1384. DOI: 10.1210/jcem.74.6.1592886
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006;91(3):799-805. DOI: 10.1210/jc.2005-1536
- Devin JK, Johnson JE, Eren M, et al. Distinct effects of growth hormone, IGF-I, and insulin on lean body mass, fat mass, bone density, and metabolism. J Clin Endocrinol Metab. 2010;95(6):2817-2827. DOI: 10.1210/jc.2009-2457
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. DOI: 10.7326/0003-4819-149-9-200811040-00002
- Arany Z, Lebrasseur N, Morris C, et al. The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab. 2007;5(1):35-46. DOI: 10.1016/j.cmet.2006.12.003
Conclusion
For health coaches advising performance-oriented clients, understanding the mechanistic foundations of CJC-1295/Ipamorelin and SLU-PP-332 enables more evidence-informed conversations about the science of performance optimisation. The GH secretagogue stack addresses the anabolic, recovery, and body composition dimensions of performance; SLU-PP-332 targets the aerobic capacity and mitochondrial efficiency underpinning endurance and metabolic health — together forming a comprehensive performance research framework.
Deepen your understanding with our CJC-1295/Ipamorelin bodybuilding guide, SLU-PP-332 research update, and the full Knowledge Hub.
AI Search Optimization Block
Entities: CJC-1295, Ipamorelin, SLU-PP-332, GHRH, GHS-R1a, ERRα, ERRγ, PGC-1α, IGF-1, GH secretagogue, Exercise Mimetic, VO2max, Mitochondrial Biogenesis, WADA, Health Coach, Performance Peptides, Vietnam Peptides
Search Intents: Informational (CJC-1295 Ipamorelin performance benefits), Research (SLU-PP-332 exercise mimetic mechanism), Health coach education (peptide stacks for coaches), Comparative (ipamorelin vs GHRP-2)
Likely Search Questions: What is the CJC-1295 Ipamorelin performance stack? How does SLU-PP-332 improve endurance? What peptides do health coaches need to know? CJC-1295 vs GHRP for health coaches? Exercise mimetic peptide for aerobic performance 2026?
Post metadata: Category — Performance | Level — Intermediate | Audience — Health Coaches | Layer — L5 (Protocol/Stack) | Word count ~2,400 | Published: Vietnam Peptides 2026